Gastroesophageal Reflux Disease and Barrett's Esophagus

Gastroesophageal reflux disease (GERD) is a common clinical problem. More frequent and extended acidic reflux episodes are characteristic of GERD, although substantial (nonacid) reflux per se is also observed in control individuals. Helicobacter pylori may protect some people from reflux disease, but others do not experience deterioration of GERD as a result of H. pylori eradication, for reasons so far unknown. Medical treatment, preferably with proton-pump inhibitors, is well established and is also recommended in endoscopy-negative forms of the disease, although the efficacy is less marked in comparison with erosive esophagitis. Surgery has emerged as an alternative to medical therapy, but the long-term results do not now appear to be as promising as was initially claimed. A number of new endoscopic techniques for the treatment of GERD have been developed, but the future for these is unclear. Barrett's esophagus develops in some patients with GERD for unknown reasons, and surveillance should be carried out in these patients due to the risk of subsequent malignant transformation. Several new approaches have been developed for detecting premalignant conditions, but these need to be investigated further. Ablative techniques are still under intensive investigation, and appear to be promising, at least in a subset of patients, although they are not devoid of major complications. Whether antireflux therapy, irrespective of the method used, can slow down the development of cancer is still an intriguing and clinically important question.

References

• 1 Sifrim D, Holloway R H, Silny J. et al . Composition of the postprandial refluxate in patients with gastro-esophageal reflux disease.  Am J Gastroenterol. 2001;  96 647-655
• 2 Vela M F, Camacho-Lubato L, Srinivasan R. et al . Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole.  Gastroenterology. 2001;  120 1599-1806
• 3 Kahrilas P J. Will impedance testing rewrite the book on GERD?.  Gastroenterology. 2001;  120 1862-1864
• 4 Gisbert J P, de Edro A, Losa C. et al . Helicobacter pylori and gastroesophageal reflux disease: lack of influence of infection on twenty-four-hour esophageal pH monitoring and endoscopic findings.  J Clin Gastroenterol. 2001;  32 210-214
• 5 Manifold D K, Anggiansah A, Rowe I. et al . Gastro-oesophageal reflux and duodenogastric reflux before and after eradication of Helicobacter pylori patients.  Eur J Gastroenterol Hepatol. 2001;  13 535-539
• 6 Warburton-Timms V J, Charlett A, Valori R M. et al . The significance of cagA+ Helicobacter pylori in reflux oesophagitis.  Gut. 2001;  49 341-346
• 7 Yamaji Y, Mitsushima T, Ikuma H. et al . Inverse background of Helicobacter pylori antibody and pepsinogen in reflux oesophagitis compared with gastric cancer: analysis of 5732 Japanese subjects.  Gut. 2001;  49 335-340
• 8 Lagergren J, Bergström R, Adami H O, Nyren O. Association between medications that relax the lower esophageal sphincter and risk of esophageal adenocarcinoma.  Ann Intern Med. 2000;  133 165-175
• 9 Shaw M J, Taylley N J, Beebe T J. et al . Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease.  Am J Gastroenterol. 2001;  96 52-57
• 10 Mones J, Clave P, Mearin F. Esophageal pH monitoring: are you sure that the electrode is properly placed?.  Am J Gastroenterol. 2001;  96 975-978
• 11 Eubanks T R, Omelanczuk P, Hillel A. et al . Pharyngeal pH measurement in patients with respiratory symptoms before and during proton pump inhibitor therapy.  Am J Surg. 201;  181 466-470
• 12 El-Serag H B, Hepworth E J, Lee P, Sonnenberg A. Gastroesophageal reflux disease is a risk factor for laryngeal and pharyngeal cancer.  Am J Gastroenterol. 2001;  96 2013-2018
• 13 Dent J, Brun J, Fendrick A M. et al . An evidence-based appraisal of reflux disease management: the Genval Workshop Report.  Gut. 1999;  44 S1-16
• 14 Howden C W, Henning J M, Huang B. et al . Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies.  Am J Gastroenterol. 2001;  96 1704-1710
• 15 Taylley N J, Lauritsen K, Tunturi-Hihnla H. et al . Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of “on-demand” therapy for 6 months.  Aliment Pharmacol Ther. 2001;  15 347-354
• 16 Moayyedi P, Feltbower R, Brown J. et al . Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in a community: a randomised controlled trial.  Lancet. 2000;  355 1665-1669
• 17 Schwizer W, Thumshirn M, Dent J. et al . Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial.  Lancet. 2001;  357 1738-1742
• 18 Fibbe C, Layer P, Keller J. et al . Esophageal motility in reflux disease before and after fundoplication: a prospective, randomized, clinical, and manometric study.  Gastroenterology. 2001;  121 5-14
• 19 Lundell L, Miettinen P, Myrvold H E. et al . Continued (5-year) follow-up of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease.  Am Coll Surg. 2001;  192 172-179
• 20 Vakil N, Treml S, Shaw M, Kirby R. The outcome of laparoscopic fundoplication for reflux disease in community practice in the USA.  Gastroenterology. 2001;  120 A16
• 21 Spechler S J, Lee E, Ahnen D. et al . Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial.  JAMA. 2001;  285 2331-2338
• 22 Filipi C J, Lehman G A, Rothstein R I. et al . Transoral, flexible endoscopic suturing for treatment of GERD: a multicenter trial.  Gastrointest Endosc. 2001;  63 416-422
• 23 Triadafilopoulos G, DiBaise J K, Nostrant T. et al . Radiofrequency energy delivery to the gastroesophageal junction for the treatment of GERD.  Gastrointest Endosc. 2001;  53 407-415
• 24 Feretis C, Benakis P, Dimoloulos C. et al . Endoscopic implantation of plexiglas (PMMA) microspheres for the treatment of GERD.  Gastrointest Endosc. 2001;  53 423-426
• 25 Fass R, Hell R W, Garewal H S. et al . Correlation of oesophageal acid exposure with Barrett's oesophagus length.  Gut. 2001;  48 310-313
• 26 Martinez d e, Ortiz A, Parrilla P. et al . Intestinal metaplasia in patients with columnar lined esophagus is associated with higher levels of duodenogastroesophageal reflux.  Ann Surg. 2001;  233 34-38
• 27 Marshall R EK, Angiansah A, Owen W A. et al . The extent of duodenogastric reflux in gastro-oesophageal reflux disease.  Eur J Gastroenterol Hepatol. 2001;  13 5-10
• 28 Vieth M, Masoud B, Meining A, Stolte M. Helicobacter pylori infection: protection against Barrett's mucosa and neoplasia?.  Digestion. 2000;  62 225-231
• 29 Weston A P, Badr A S, Topalovski M. et al . Prospective evaluation of the prevalence of gastric Helicobacter pylori infection with GERD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenocarcinoma.  Am J Gastroenterol. 2000;  95 387-394
• 30 Morris C D, Armstrong G R, Bigley G. et al . Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.  Am J Gastroenterol. 2001;  96 990-996
• 31 Weston A P, Banerjee S K, Sharma P. et al . p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression.  Am J Gastroenterol. 2001;  96 1355-1365
• 32 Reid B J. p53 and neoplastic progression in Barrett's esophagus.  Am J Gastroenterol. 2001;  96 1321-1323
• 33 Bhargava P, Eisen G M, Holterman D A. et al . Endoscopic mapping and surrogate markers for better surveillance in Barrett's esophagus.  Am J Clin Pathol. 2000;  114 552-563
• 34 Schnell T G, Sontag S J, Chejfec G. et al . Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia.  Gastroenterology. 2001;  120 1607-1619
• 35 Buttar N S, Wang K K, Sebo T J. et al . Extent of high-grade dysplasia in Barrett's esophagus correlated with risk of adenocarcinoma.  Gastroenterology. 2001;  120 1630-1639
• 36 Skacel M, Petras R E, Gramlich T L. et al . The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression.  Am J Gastroenterol. 2000;  95 3383-3387
• 37 Reid B J, Blount P L, Feng Z, Levine D S. Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia.  Am J Gastroenterol. 2000;  95 3089-3096
• 38 Guelrud M, Herrera I, Essenfeld H, Casro J. Enhanced magnification endoscopy: a new technique to identify specialized intestinal metaplasia in Barrett's esophagus.  Gastrointest Endosc. 2001;  53 559-565
• 39 Canto M IF, Setrakian S, Willis J. et al . Methylene blue-directed biopsies improve detection of intestinal metaplasia and dysplasia in Barrett's esophagus.  Gastrointest Endosc. 2000;  51 560-568
• 40 Kiesslich R, Hahn M, Herrmann G, Jung M. Screening for specialized columnar epithelium with methylene blue: chromoendoscopy in patients with Barrett's esophagus and a normal control group.  Gastrointest Endosc. 2001;  53 47-52
• 41 Dave U, Shousha S, Westaby D. Methylene blue staining: is it really useful in Barrett's esophagus?.  Gastrointest Endosc. 2001;  53 333-335
• 42 Endlicher E, Knuechel R, Hauser T. et al . Endoscopic fluorescence detection of low and high grade dysplasia in Barrett's esophagus using systemic or local 5-aminolaevulinic acid sensitisation.  Gut. 2001;  48 314-319
• 43 Poneros J M, Brand S, Bouma B E. et al . Diagnosis of specialized intestinal metaplasia by optical coherence tomography.  Gastroenterology. 2001;  120 7-12
• 44 Wallace M B, Perleman L T, Backman V. et al . Endoscopic detection of dysplasia in patients with Barrett's esophagus using light-scattering spectroscopy.  Gastroenterology. 2000;  119 677-682
• 45 Georgakoudi I, Jacobson B C, van Dam J. et al . Fluorescence, reflectance, and light-scattering spectroscopy for evaluating dysplasia in patients with Barrett's esophagus.  Gastroenterology. 2001;  120 1620-1629
• 46 Hofstetter W L, Peters J H, DeMeester T R. et al . Long-term outcome of antireflux surgery in patients with Barrett's esophagus.  Ann Surg. 2001;  234 532-539
• 47 Chen L Q, Hu C Y, Gaboury L. et al . Proliferative activity in Barrett's esophagus before and after antireflux surgery.  Ann Surg. 2001;  234 172-180
• 48 Peters F T, Ganesh S, Kuipers E J. et al . Effect of elimination of acid reflux on epithelial cell proliferative activity of Barrett esophagus.  Scand J Gastroenterol. 2000;  35 1238-1244
• 49 Tigges H, Fuchs K H, Maroske J. et al . Combination of endoscopic argon plasma coagulation and antireflux surgery for treatment of Barrett's esophagus.  J Gastrointest Surg. 2001;  5 251-259
• 50 Sampliner R E, Faigel D, Fennerty M B. et al . Effective and safe endoscopic reversal of nondysplastic Barrett's esophagus with thermal electrocoagulation combined with high-dose acid inhibition: a multicenter study.  Gastrointest Endosc. 2001;  53 554-558
• 51 Fass R, Garewal H S, Hayden C W. et al . Preferential repair by squamous epithelium of thermal induced injury to the proximal stomach in patients undergoing ablation of Barrett's esophagus.  Gastrointest Endosc. 2001;  53 711-716
• 52 Ackroyd R, Brown N J, Davs M F. et al . Photodynamic therapy for dysplastic Barrett's oesophagus: a prospective, double blind, randomised, placebo-controlled trial.  Gut. 2000;  47 612-617
• 53 Panjehpour M, Overholt B F, Haydek J M, Lee S G. Results of photodynamic therapy for ablation of dysplasia and early cancer in Barrett's esophagus and effect of oral steroids on stricture formation.  Am J Gastroenterol. 2000;  95 2177-2184
• 54 Nijhawan P K, Wang K K. Endoscopic mucosal resection for lesions with endoscopic features suggestive of malignancy and high-grade dysplasia within Barrett's esophagus.  Gastrointest Endosc. 2000;  52 328-332